Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Long-Term Debt Repayments (2021 - 2024)

Standard Biotools (LAB) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $55.0 million as the latest value for Q4 2024.

  • Quarterly Long-Term Debt Repayments rose 4300.0% to $55.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $55.0 million through Sep 2025, up 482.5% year-over-year, with the annual reading at $63.2 million for FY2024, 2933.7% up from the prior year.
  • Long-Term Debt Repayments for Q4 2024 was $55.0 million at Standard Biotools, up from $8.2 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $55.0 million in Q4 2024, with the low at $501000.0 in Q1 2021.
  • Average Long-Term Debt Repayments over 4 years is $9.2 million, with a median of $1.0 million recorded in 2023.
  • The sharpest move saw Long-Term Debt Repayments surged 1264.87% in 2022, then soared 4300.0% in 2024.
  • Over 4 years, Long-Term Debt Repayments stood at $501000.0 in 2021, then soared by 1264.87% to $6.8 million in 2022, then plummeted by 81.72% to $1.2 million in 2023, then skyrocketed by 4300.0% to $55.0 million in 2024.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $55.0 million, $8.2 million, and $1.2 million for Q4 2024, Q1 2024, and Q4 2023 respectively.